complications, according to some new study from the Countrywide Institutes

complications, according to some new study from the Countrywide Institutes of Overall health.
Offering a mix of medicines for the newborns of HIV-positive females cuts the infants probability of getting to be contaminated using the virus that causes AIDS in 50 %, in accordance to the Nationwide Institutes of Health (NIH).
Usually, HIV-positive girls are presented antiviral medication during their being pregnant to reduce the risk of passing on their infections to their infants, both inside the womb, during labor and delivery, or when they breast feed. With out that maternal drug therapy, between 25 and 50 per cent of these newborns will grow to be infected.
Investigators together Import 8 pin Socket with the Nationwide Institutes of Health and an international network of hospitals and healthcare facilities looked at three drug therapies aimed at reducing mother-to-child HIV transmissions.  
Researchers found that the standard antiviral drug zidovudine (AZT), combined with another drug called nevirapine, significantly decrease transmission of the AIDS virus to newborns compared to AZT alone. Nevarapine lowers the amount of virus within the blood.
NIH s Heather Watts, who co-authored the research, says the females in the trial did not know before labor and shipping and delivery that they were HIV-positive.
In some cases they had a negative HIV test earlier in pregnancy and then were retested throughout labor and shipping and were found to be positive, Watts says, or in some cases they knew they were positive but they hadn t come in for care, and then just showed up for shipping.
The VAG OBD2 16PIN TO DB9 cable examine, which involved 1,600 infants, was conducted within the U.S., Brazil, Argentina and South Africa amongst 2004 and 2010.  The newborns received one of 3 antiviral treatments within 48 hours after birth.
One group got AZT for six weeks.  A second group received AZT plus nevirapine for that time. The third group of infants got a six-week regimen of AZT, plus 3TC, which is similar to AZT, and the protease inhibitor